Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

April’s top stories: CN Bio licenced Hepatitis B drug programme, Astellas agreed to acquire Ogeda for €800m

CN Bio licenced a Hepatitis B drug discovery programme from Bristol-Myers Squibb and Astellas Pharma agreed to acquire Belgium’s Ogeda for €800m. wraps up the key headlines from April.

Go Top